Professional Advisory Services’s Oncolytics Biotech ONCY Stock Holding History

Professional Advisory Services’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20K	Buy	30,000 +10,000	+50%	+$8.12K	﹤0.01%	89
2026 Q2	$19K	Hold	20,000	–	–	﹤0.01%	92
2026 Q1	$17K	Hold	20,000	–	–	﹤0.01%	80
2025 Q4	$17K	Hold	20,000	–	–	﹤0.01%	80
2025 Q3	$28K	Hold	20,000	–	–	﹤0.01%	81
2025 Q2	$15K	Buy	20,000 +5,000	+33%	+$2.65K	﹤0.01%	81
2025 Q1	$8K	Buy	15,000 +5,000	+50%	+$3.66K	﹤0.01%	80
2024 Q4	$9K	Hold	10,000	–	–	﹤0.01%	76
2024 Q3	$9K	Hold	10,000	–	–	﹤0.01%	79
2024 Q2	$10K	Hold	10,000	–	–	﹤0.01%	76
2024 Q1	$11K	Buy	+10,000	New	+$11.2K	﹤0.01%	75

Other funds holding ONCY

EFG

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Professional Advisory Services's ONCY Position: Q3 2026 in Review

Professional Advisory Services increased its Oncolytics Biotech (ONCY) stake by 50% in Q3 2026, buying an estimated $8.12K and bringing the position to 30,000 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #89.

Professional Advisory Services first reported a position in ONCY in Q1 2024 and has held it in 11 quarters since. The position peaked at $28K in Q3 2025. 4 funds tracked by Wall St. Rank hold ONCY as of Q3 2026.

Professional Advisory Services held 30,000 shares of Oncolytics Biotech worth $20K as of Q3 2026.
Professional Advisory Services bought 10,000 Oncolytics Biotech shares in Q3 2026, an estimated $8.12K.
Oncolytics Biotech made up ﹤0.01% of Professional Advisory Services's portfolio in Q3 2026, its #89 holding.
Professional Advisory Services first reported a position in Oncolytics Biotech in Q1 2024 and has held it in 11 quarters since.
Professional Advisory Services's Oncolytics Biotech position peaked at $28K in Q3 2025.
4 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2026.

Based on Professional Advisory Services's 13F filing for Q3 2026, filed 8 Oct 2026.